VEGFR resistance transcriptome in cancer
VEGFR has become an important target for tumor treatment. Targeted drugs against VEGFR, such as small - molecule tyrosine kinase inhibitors (TKIs) and monoclonal antibodies, block the activity of VEGFR, inhibit tumor angiogenesis, and thereby achieve the goal of inhibiting tumor growth and spread. However, in clinical applications, tumor cells often develop resistance to these VEGFR - targeted drugs, that is, VEGFR resistance, leading to a decrease in treatment efficacy or treatment failure.